CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Oct. 31, 2011	Oct. 31, 2010
Cash flows from operating activities
Net income	$ 6,220	$ 4,975
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	1,677	1,628
Amortization	2,289	1,319
Stock-based compensation expense	931	765
Amortization of debt issuance costs	95	79
Loss (gain) on disposal of fixed assets	3	(11)
Deferred income taxes	(351)	(538)
Excess tax benefits from stock-based compensation	(218)	(20)
Changes in assets and liabilities, net of assets acquired and liabilities assumed:
Accounts receivable	6,614	(2,177)
Inventories	(1,906)	1,368
Prepaid expenses and other current assets	(2,440)	(882)
Accounts payable and other current liabilities	(8,275)	(5,655)
Income taxes payable	3,057	2,369
Net cash provided by operating activities	7,696	3,220
Cash flows from investing activities
Capital expenditures	(1,290)	(1,192)
Proceeds from disposal of fixed assets		29
Acquisition of Gambro Water	(517)	(20,600)
Acquisition of the Byrne Medical Business	(95,900)
Other, net	(53)	(98)
Net cash used in investing activities	(97,760)	(21,861)
Cash flows from financing activities
Borrowings under term credit facility, net of debt issuance costs	49,649
Borrowings under revolving credit facility, net of debt issuance costs	46,946	20,500
Repayments under term loan facility	(2,500)	(2,500)
Repayments under revolving credit facility	(3,000)	(6,000)
Proceeds from exercises of stock options	390	81
Excess tax benefits from stock-based compensation	218	20
Purchases of treasury stock	(293)	(67)
Net cash provided by financing activities	91,410	12,034
Effect of exchange rate changes on cash and cash equivalents	(110)	(51)
Increase (decrease) in cash and cash equivalents	1,236	(6,658)
Cash and cash equivalents at beginning of period	18,410	22,612
Cash and cash equivalents at end of period	$ 19,646	$ 15,954